Tegafur: Uses, Interactions, Mechanism of Action - DrugBank Online
Tegafur is an antineoplastic agent used in combination with other anticancer medications to treat advanced gastric and colorectal cancers.
Tegafur - Wikipedia
Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU. [1] It was patented in 1967 and approved for medical use in 1972. [2]
Tegafur/gimeracil/oteracil (S-1) approved for the treatment of …
S-1 is a combination of three pharmacological compounds, namely tegafur, gimeracil, and oteracil potassium. Tegafur is a prodrug of 5-fluorouracil (5-FU), an oral fluoropyrimidine, and it has been developed as a replacement for infusional 5-FU therapy.
Tegafur-uracil: Uses, Interactions, Mechanism of Action
2015年11月17日 · Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.
Tegafur | C8H9FN2O3 | CID 5386 - PubChem
2016年4月11日 · Tegafur is an organohalogen compound and a member of pyrimidines. Tegafur (INN, BAN, USAN) is a prodrug of [DB00544] (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers.
Tegafur/gimeracil/oteracil - Wikipedia
Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, [3] and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers.
Teysuno | European Medicines Agency (EMA)
2017年3月2日 · The main active substance in Teysuno, tegafur, is a cytotoxic medicine (a medicine that kills rapidly dividing cells, such as cancer cells). Tegafur is converted to the medicine fluorouracil in the body, but more is converted in tumour cells than in normal tissues.
Tegafur/uracil - Wikipedia
Tegafur/uracil (abbreviation: UFT [1]) is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer. UFT is an oral formulation combining uracil (a competitive inhibitor of dihydropyrimidine dehydrogenase), and tegafur (a bioavailable 5-fluorouracil (5-FU) prodrug) in a 4:1 molar ratio. [1]
Definition of tegafur-uracil - NCI Drug Dictionary - NCI
A formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4).
Tegafur: Uses, Dosage, Side Effects, FAQ - MedicinesFAQ
2023年9月19日 · Tegafur is an antineoplastic agent used in combination with other anticancer medications to treat advanced gastric and colorectal cancers. Indicated for the treatment of cancer usually in combination with other biochemically modulating drugs.